|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
RNA interference
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2021
gptkb:FDA
|
|
gptkbp:class
|
lipid-lowering agents
|
|
gptkbp:clinical_trial
|
gptkb:ORION-1
gptkb:ORION-10
gptkb:ORION-11
high
Phase 3
ongoing studies
integrated into treatment plans
|
|
gptkbp:collaborations
|
gptkb:University_of_Oxford
|
|
gptkbp:contraindication
|
severe hypersensitivity
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:dosage_form
|
injection solution
|
|
gptkbp:education
|
informed consent required
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:feedback
|
positive outcomes reported
|
|
gptkbp:frequency
|
twice a year
|
|
gptkbp:healthcare
|
available through specialty pharmacies
prescribed by cardiologists
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Leqvio
|
|
gptkbp:indication
|
hyperlipidemia
|
|
gptkbp:ingredients
|
gptkb:inclisiran
|
|
gptkbp:interacts_with
|
none significant
|
|
gptkbp:invention
|
gptkb:Novartis
|
|
gptkbp:is_atype_of
|
C10 A X14
|
|
gptkbp:is_monitored_by
|
lipid levels
|
|
gptkbp:is_used_for
|
lowering LDL cholesterol
|
|
gptkbp:lifespan
|
approximately 20 days
|
|
gptkbp:market
|
gptkb:2022
|
|
gptkbp:marketed_as
|
gptkb:brand
|
|
gptkbp:marketing_strategy
|
direct-to-consumer advertising
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
2 D1 A1 D1 D1 D
|
|
gptkbp:packaging
|
single-dose prefilled syringe
|
|
gptkbp:pharmacokinetics
|
subcutaneous absorption
lowers PCS K9 levels
|
|
gptkbp:population
|
primarily older adults
adults with cardiovascular disease
|
|
gptkbp:price
|
approximately $6,000 per year
|
|
gptkbp:provides_information_on
|
recommended for high-risk patients
AHA/ ACC guidelines
|
|
gptkbp:receives_funding_from
|
covered by insurance
funded by Novartis
|
|
gptkbp:regulatory_compliance
|
gptkb:European_Medicines_Agency
|
|
gptkbp:research_focus
|
cardiovascular health
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:sales
|
available in multiple countries
|
|
gptkbp:scholarships
|
available for patients
|
|
gptkbp:side_effect
|
fatigue
muscle pain
nausea
diarrhea
mandatory reporting
injection site reactions
|
|
gptkbp:social_structure
|
C22 H30 N4 O4 S
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:supply_chain
|
managed by Novartis
|
|
gptkbp:treatment
|
improved quality of life
reduced cardiovascular events
|
|
gptkbp:type_of
|
1633024-00-4
|
|
gptkbp:type_of_care
|
high adherence rates
|
|
gptkbp:type_of_insurance
|
covered under most plans
|
|
gptkbp:bfsParent
|
gptkb:Alnylam_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|